> Detailanzeige

Cortellini, Alessio; Vitale, Maria G.; De Galitiis, Federica; Di Pietro, Francesca R.; Berardi, Rossana; Torniai, Mariangela; De Tursi, Michele; Grassadonia, Antonino; Di Marino, Pietro; Santini, Daniele; Zeppola, Tea; Anesi, Cecilia; Gelibter, Alain; Occhipinti, Mario Alberto; Botticelli, Andrea; Marchetti, Paolo; Rastelli, Francesca; Pergolesi, Federica; Tudini, Marianna; Silva, Rosa Rita; Mallardo, Domenico; Vanella, Vito; Ficorella, Corrado; Porzio, Giampiero;

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
  • Beteiligte: Cortellini, Alessio; Vitale, Maria G.; De Galitiis, Federica; Di Pietro, Francesca R.; Berardi, Rossana; Torniai, Mariangela; De Tursi, Michele; Grassadonia, Antonino; Di Marino, Pietro; Santini, Daniele; Zeppola, Tea; Anesi, Cecilia; Gelibter, Alain; Occhipinti, Mario Alberto; Botticelli, Andrea; Marchetti, Paolo; Rastelli, Francesca; Pergolesi, Federica; Tudini, Marianna; Silva, Rosa Rita; Mallardo, Domenico; Vanella, Vito; Ficorella, Corrado; Porzio, Giampiero;
  • Erschienen: Springer Science and Business Media LLC, 2019
  • Erschienen in: Journal of Translational Medicine
  • Sprache: Englisch
  • DOI: 10.1186/s12967-019-02132-x
  • ISSN: 1479-5876
  • Schlagwörter: General Biochemistry, Genetics and Molecular Biology ; General Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Fatigue was reported as the most common any-grade adverse event (18.3%), and the most common grade 3 or higher immune-related adverse event (irAE) (0.89%) in patients receiving PD-1/PD-L1 checkpoint inhibitors in clinical trial.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>The aim of this retrospective multicenter study was to evaluate the correlations between “early ir-fatigue”, “delayed ir-fatigue”, and clinical outcomes in cancer patients receiving PD-1/PD-L1 inhibitors in clinical practice.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>517 patients were evaluated. After the 12-weeks landmark selection, 386 (74.7%) patients were eligible for the clinical outcomes analysis. 40.4% were NSCLC, 42.2% were melanoma, 15.3% renal cell carcinoma and 2.1% other malignancies. 76 patients (19.7%) experienced early ir-fatigue (within 1 month from treatment commencement), while 150 patients (38.9%) experienced delayed ir-fatigue. Early ir-fatigue was significantly related to shortened PFS (HR = 2.29 [95% CI 1.62–3.22], p &lt; 0.0001) and OS (HR = 2.32 [95% CI 1.59–3.38], p &lt; 0.0001) at the multivariate analysis. On the other hand, we found a significant association between the occurrence of early ir-fatigue, ECOG-PS ≥ 2 (p &lt; 0.0001), and disease burden (p = 0.0003). Delayed ir-fatigue was not significantly related to PFS nor OS.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Early ir-fatigue seems to be negative prognostic parameter, but to proper weight its role we must to consider the predominant role of performance status, which was related to early ir-fatigue in the study population.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang